Prevalence of HCV in beta-thalassemia major patients visiting tertiary care hospitals in Lahore - Pakistan

被引:0
作者
Nazir, Shahid [1 ]
Faraz, Ahmad [1 ]
Shahzad, Naeem [2 ]
Ali, Nasir [3 ]
Khan, Muhammd Arman [4 ]
Iqbal, Mazhar [2 ]
Khan, Muhammad Farhan [4 ]
Ahmed, Toraiz [5 ]
Rakha, Allah [6 ]
Sabzwari, Javed [2 ]
机构
[1] Ittefaq Hosp Trust, Dept Pathol, Lahore, Pakistan
[2] Sheikh Zaid Med Complex, Dept Biochem, Lahore, Pakistan
[3] Univ Fed Parana, Curitiba, Parana, Brazil
[4] Univ Vet & Anim Sci, Inst Biochem & Biotechnol, Lahore, Pakistan
[5] Univ Vet & Anim Sci, Dept Epidemiol, Lahore, Pakistan
[6] Univ Hlth Sci, Lahore, Pakistan
来源
ADVANCEMENTS IN LIFE SCIENCES | 2018年 / 5卷 / 04期
关键词
Prevalence; HCV; Thalassemia; Transfusion Transmitted Infection;
D O I
暂无
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Post-transfusion hepatitis (PTH) is majorly caused by hepatitis C virus (HCV). So, recipients of blood/blood products, post-transfusion hepatitis (PTH), renal dialysis patients and intravenous drug users all represent high-risk groups for infection. The aim of the present research was to determine the prevalence of HCV antibody in beta-thalassemia major patients visiting different tertiary care hospital in Lahore, Pakistan. Methods: HCV seroprevalence and risk factors were studied in 200 beta-thalassemia major patients (24 females, 176 males) with different age groups by second generation ELISA during January 2013 to May 2013. Confirmed beta-thalassemia major patients from three different tertiary care hospitals were selected with special reference to age, age at the time of diagnosis, frequency of transfusion and present clinical status. Results: Among 200 patients, 82 (41%) were found reactive for HCV antibody with age range of 2 to 18 years with mean age of 8.5 years. Conclusion: This study showed that hemodialysis patients and beta-thalassemia sufferers were at higher risk of having HCV infection; the prevalence being 41%.
引用
收藏
页码:197 / 201
页数:5
相关论文
共 50 条
  • [41] Beta-thalassemia major alters sofosbuvir/ ledipasvir exposure in Hepatitis C virus infected adolescent patients
    El-Baraky, Iman A.
    Abbassi, Maggie M.
    Ebied, Fatma S.
    Hassany, Mohamed
    Sabry, Nirmeen A.
    El-Sayed, Manal H.
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2021, 45 (05)
  • [42] Prevalence of occult hepatitis C virus infection in Iranian patients with beta thalassemia major
    Bastani, Mohammad-Navid
    Bokharaei-Salim, Farah
    Keyvani, Hossein
    Esghaei, Maryam
    Monavari, Seyed Hamidreza
    Ebrahimi, Mojtaba
    Garshasebi, Saba
    Fakhim, Shahin
    ARCHIVES OF VIROLOGY, 2016, 161 (07) : 1899 - 1906
  • [43] Evaluation of Serum Ferritin Levels in Children of South Punjab (Pakistan) having Beta-Thalassemia Major with Iron-Overload Treated with Deferasirox
    Batool, Tayyaba
    Ul Amin, Muhammad Roh
    Iqbal, Mujahid
    Malik, Farooq
    Khan, Irfan
    Younas, Nadeem Shahid
    PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2021, 15 (09): : 2464 - 2466
  • [44] Liver fibrosis in young Egyptian beta-thalassemia major patients: relation to hepatitis C virus and compliance with chelation
    Elalfy, Mohsen S.
    Esmat, Gamal
    Matter, Randa M.
    Aziz, Hesham E. Abdel
    Massoud, Walid A.
    ANNALS OF HEPATOLOGY, 2013, 12 (01) : 54 - 61
  • [45] Renal Dysfunction in Patients with Beta-Thalassemia Major Receiving Iron Chelation Therapy either with Deferoxamine and Deferiprone or with Deferasirox
    Economou, Marina
    Printza, Nikoletta
    Teli, Aikaterini
    Tzimouli, Vassiliki
    Tsatra, Ioanna
    Papachristou, Fotis
    Athanassiou-Metaxa, Miranda
    ACTA HAEMATOLOGICA, 2010, 123 (03) : 148 - 152
  • [46] Evaluation of serum Fibroblast growth factor-23 in patients with beta-thalassemia major compared to healthy population
    Saki, Forough
    Omrani, Gholamhossein Ranjbar
    IRANIAN JOURNAL OF PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2022, 12 (03) : 182 - 189
  • [47] Evaluation of the incidence of sensorineural hearing loss in beta-thalassemia major patients under regular chelation therapy with desferrioxamine
    Karimi, M
    Asadi-Pooya, AA
    Khademi, B
    Asadi-Pooya, K
    Yarmohammadi, H
    ACTA HAEMATOLOGICA, 2002, 108 (02) : 79 - 83
  • [48] Activin-A is elevated in patients with thalassemia major and double heterozygous sickle cell/beta-thalassemia and correlates with markers of hemolysis and bone mineral density
    Voskaridou, Ersi
    Ntanasis-Stathopoulos, Ioannis
    Christoulas, Dimitrios
    Dimopoulou, Maria
    Komninaka, Veroniki
    Repa, Konstantina
    Papatheodorou, Athanasios
    Terpos, Evangelos
    ANNALS OF HEMATOLOGY, 2019, 98 (07) : 1583 - 1592
  • [49] Activin-A is elevated in patients with thalassemia major and double heterozygous sickle cell/beta-thalassemia and correlates with markers of hemolysis and bone mineral density
    Ersi Voskaridou
    Ioannis Ntanasis-Stathopoulos
    Dimitrios Christoulas
    Maria Dimopoulou
    Veroniki Komninaka
    Konstantina Repa
    Athanasios Papatheodorou
    Evangelos Terpos
    Annals of Hematology, 2019, 98 : 1583 - 1592
  • [50] Prevalence of erectile dysfunction and associated factors among males visiting family medicine clinics in a Tertiary Care Hospital in Karachi, Pakistan
    Saeed, Rabeeya
    Amin, Faridah
    Durrani, Noureen
    Saif, Syed M. Ali
    Zafar, Muhammad Talha
    JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2021, 10 (03) : 1294 - 1300